Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 ( CB1 ), binds to hCB1 and hCB2 with K i of 0.3 nM and 613 nM.
Products | Products > Disease Areas > Obesity | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pain | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Cannabinoid Receptor | Products > Signaling Pathways > Arrestin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.